Fulford (India) Ltd vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of Fulford (India) Ltd (FULFORD) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads FULFORD vs TORNTPHARM on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability31
  • Growth02
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
77.60
0.00
P/B ratio
18.67
0.00%
Dividend yield
0.76%
₹46.36
EPS
₹63.92

Profitability

FULFORD takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

10.60%
Return on equity
27.40%
18.00%
Return on capital
15.00%
38.00%
EBITDA margin
33.00%
25.71%
Net margin
15.29%

Growth

TORNTPHARM takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-16.90%
Revenue CAGR (3Y)
13.27%
0.00%
Profit CAGR (3Y)
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹0 Cr
Market cap
₹1.68L Cr
₹70 Cr
Revenue
₹13,980 Cr
₹18 Cr
Net profit
₹2,138 Cr
0.00
Debt / equity
1.69
Fulford (India) Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 220%"]
  • ["Stock is trading at 8.03 times its book value", "The company has delivered a poor sales growth of -14.7% over past five years.", "Company has a low return on equity of 13.1% over last 3 years."]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
Fulford (India) Ltd full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

FULFORD vs TORNTPHARM: Share Price, Valuation & Which to Buy | DocStoX